Teleflex

Teleflex, Inc. provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The firm designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teleflex reports Q4 growth amidst challenges, eyes revenue acceleration

Teleflex's Q4 performance showed resilience with revenue growth and strategic acquisitions. While facing challenges like supply chain disruptions and UroLift revenue decline, the company is focused on margin expansion and disciplined growth. Opportunities lie in revenue acceleration, international expansion, and leveraging high-growth product categories.

Teleflex reports robust Q1 earnings, eyes growth amid challenges

Teleflex's Q1 2023 results reflect strong performance and strategic focus on sustainable growth, supported by geographic revenue growth and product category contributions.
While facing challenges in specific product lines and supply chain issues, the company maintains a disciplined approach to deals and cost management.
Opportunities lie in revised revenue guidance, product performance, and market improvements, positioning Teleflex for continued success in 2023.

Teleflex reports revenue growth and strategic acquisitions drive future outlook

Teleflex revised its 2023 financial guidance with revenue growth of 5.5% to 6.25% and adjusted EPS of $13 to $13.60. Despite challenges in certain product segments, the company remains confident in achieving its Long Range Plan growth objectives. The focus on integrating acquisitions like Palette and leveraging high-growth products positions Teleflex for continued success.

Teleflex reports robust Q3 results, eyes growth amidst challenges

Teleflex's Q3 performance reflects revenue and EPS growth, driven by operational improvements.
Despite challenges from GLP-1 impact and tax rate increases, the company remains optimistic.
Opportunities lie in market expansion, M&A activities, and product uniqueness strategies.
Overall, Teleflex's strong financials and strategic initiatives position it for continued growth.

Teleflex reports solid 2023 performance, eyes growth in Urology market

Teleflex's 2023 performance showed revenue growth and strong cash flow, with guidance for 2024 indicating continued growth and margin targets.
Despite challenges like declining EPS and recall impacts, the company aims for high EPS growth and sees opportunities in new markets and product expansions.
Confidence in meeting targets, pursuing strategic initiatives, and navigating market challenges position Teleflex for growth and profitability in the coming years.
Balancing financial performance with strategic investments and operational improvements will be key for Teleflex to capitalize on growth opportunities and overcome challenges.

Teleflex reports solid Q1 performance, eyes growth through acquisitions

Teleflex's Q1 2024 performance was solid, with revenue growth, margin expansion, and strong cash flow. Despite challenges like market multiples and recall impacts, the company is focused on growth opportunities and disciplined acquisitions to drive future success.

Teleflex reports solid Q2 growth, eyes M&A and product innovation

Teleflex's Q2 performance reflects steady growth, driven by strong results in key segments and product categories.
Despite challenges in certain areas, the company's strategic initiatives, including acquisitions and product innovation, position it well for future success.
With a focus on revenue growth, operational efficiency, and shareholder value, Teleflex is poised to capitalize on opportunities and navigate challenges effectively.

Teleflex reports solid Q3 earnings, eyes growth amid challenges

Teleflex's Q3 2024 performance showcased revenue growth, margin improvement, and strategic acquisitions driving increased revenue guidance for the year.
While facing challenges in specific product categories, the company's focus on innovation, market expansion, and financial strength positions it well for future growth.
Opportunities in expanding markets, disciplined capital allocation, and strong cash flow generation underscore Teleflex's resilience and potential for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teleflex, Inc. provides medical technology products which enable healthcare providers to improve patient outcomes and enhance patient and provider safety. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.

Teleflex (TFX) delivered earnings and revenue surprises of 17.13% and 4.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Teleflex (TFX) Q2 Earnings and Revenues Top Estimates

Shares of Teleflex (NYSE:TFX) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share increased 73.58% over the past year to $3.35, which beat the estimate of $2.87.

Recap: Teleflex Q2 Earnings

WAYNE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 27, 2021.

Teleflex Reports Second Quarter 2021 Results and Full Year Outlook

The stock price of ​Teleflex,best known for its single-use medical devices for common diagnostic and therapeutic procedures, reached an all-time high of $440 in April this year before a recent sell-off, after the Centers for Medicare and Medicaid Services proposed new rules, including one that.

Will Teleflex Stock Rise After A 7% Fall Last Week?

Teleflex (TFX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Teleflex (TFX) Moves 3.8% Higher: Will This Strength Last?

Strong segmental performance in America and Asia is driving the top line for Teleflex (TFX).

Here's Why You Should Add Teleflex (TFX) to Your Portfolio

Shares of Teleflex Inc. tumbled 10.9% toward an 8-month low in afternoon trading Thursday, enough to pace the S&P 500 decliners, and to put them on track for the biggest one-day percentage selloff since March 2020. Teleflex is a medical technology company, with products in the fields of urology, cardiac and respiratory care and emergency medicine.

Teleflex stock tumbles toward 8-month low, paces S&P 500 decliners

WAYNE, Pa., July 15, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 29, 2021.

Teleflex Announces Second Quarter 2021 Earnings Conference Call Information

Real-World Claims Data Presented at Annual European Association of Urology Congress Reveal Overall Complication Rates are Lowest after Treatment with the UroLift System Real-World Claims Data Presented at Annual European Association of Urology Congress Reveal Overall Complication Rates are Lowest after Treatment with the UroLift System

Largest U.S. Healthcare Claims and Utilization Analysis for BPH Procedures Reveals Lowest Overall Complication Rates and Consistent Durability after Treatment with Minimally Invasive UroLift System

Presentations to Provide New Insights on the Real-World Effectiveness and Durability of Leading Minimally Invasive Procedure for Enlarged Prostate Presentations to Provide New Insights on the Real-World Effectiveness and Durability of Leading Minimally Invasive Procedure for Enlarged Prostate

Teleflex Announces Real-World Clinical Data Presentations of the UroLift® System at the 36th Annual European Association of Urology Congress

WAYNE, Pa., June 28, 2021 (GLOBE NEWSWIRE) -- Today, Teleflex Incorporated (NYSE:TFX), a leading global provider for healthcare supplies and services, announced it has completed the previously announced divestiture of a significant portion of its Respiratory business to Medline Industries, Inc. (“Medline”) for $286 million in cash, reduced by $12 million in working capital not transferring to Medline.

Teleflex Completes Divestiture of Respiratory Assets to Medline Industries

Teleflex survey finds “extreme bathroom planning” to accommodate urinary symptoms common with an enlarged prostate (BPH) impacts daily activities Teleflex survey finds “extreme bathroom planning” to accommodate urinary symptoms common with an enlarged prostate (BPH) impacts daily activities

New Data Suggest Men with Urinary Symptoms Often Anticipate Bathroom Needs and Avoid Events and Activities They Enjoy

The UroLift System remains a major contributor to Teleflex (TFX) revenues.

Teleflex (TFX) Procedure Volume Recovers as Pandemic Subsides

WAYNE, Pa., June 07, 2021 (GLOBE NEWSWIRE) -- Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Raymond James 2021 Human Health Innovation Conference on Monday, June 21, 2021 at 8:40 a.m. (ET).

Teleflex to Present at the Raymond James 2021 Human Health Innovation Conference

Teleflex started 2021 on a solid note and raised the full year guidance nominally.

Teleflex: Moving Along

On the strength of a successful 2020 campaign, Teleflex (TFX) doubles the awareness for UroLift in the targeted population of men with BPH.

TeleFlex (TFX) Urolift Grows, Organic Sales Hit by Pandemic

Teleflex Incorporated (NYSE: TFX) has agreed to sell a significant portion of its Respiratory business to Medline Industries Inc for $286 million in cash, reduced by $12 million in working capital not transferring to Medline. The divested product lines include oxygen and aerosol therapy, active humidification, non-invasive ventilation, and incentive spirometers.

Teleflex To Divest Certain Respiratory Assets To Medline For $286M

Total consideration is $286 million, reduced by $12 million of working capital to be retained by Teleflex Assets to be divested generated $139M in 2020 revenue, with 2021 growth expected to be approximately flat 2021 headwinds are estimated at $28-32 million in revenue and $0.10-$0.15 in adjusted diluted earnings per share Teleflex is maintaining its current 2021 adjusted diluted earnings per share guidance range

Teleflex Signs Definitive Agreement to Sell Certain Respiratory Assets and Reaffirms Adjusted EPS Guidance

WAYNE, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- May 11, 2021 – Thomas Powell, Executive Vice President and CFO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021 at 3:00 p.m. (ET).

Teleflex to Present at the UBS Global Healthcare Virtual Conference

Teleflex Incorporated (TFX) CEO Liam Kelly on Q1 2021 Results - Earnings Call Transcript

The acquisition of Z-Medica and an increase in sales of new products contribute to Teleflex's (TFX) revenue growth in Americas in Q1

Teleflex (TFX) Beats on Q1 Earnings and Revenues, Raises View

Shares of Teleflex (NYSE:TFX) fell 0.3% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 5.51% year over year to $2.87, which beat the estimate of $2.42.

Teleflex: Q1 Earnings Insights

First quarter 2021 revenues of $633.9 million, up 0.5% versus prior year period on an as-reported basis; down 2.6% on a constant currency basis

Teleflex Reports First Quarter 2021 Results

WAYNE, Pa., April 27, 2021 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Bank of America Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 at 8:00 a.m. (ET).

Teleflex to Present at the Bank of America Securities 2021 Virtual Health Care Conference

Live Webcast is scheduled at 8:00 a.m. (ET) on Thursday, April 29, 2021 Live Webcast is scheduled at 8:00 a.m. (ET) on Thursday, April 29, 2021

News for Teleflex Stock (TFX)